NCT02029313View on ClinicalTrials.gov

Safety and the Pharmacokinetic Study of Characteristics of MKT-N2 (Montelukast) and Singulair® (Montelukast Sodium)to Treat Asthma

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

November 30, 2013

Primary Completion Date

January 31, 2014

Study Completion Date

March 31, 2014

Conditions
Asthma and Allergic Rhinitis
Interventions
DRUG

Montelukast

DRUG

Montelukast sodium

Trial Locations (1)

Unknown

Inha University Hospital, Incheon

Sponsors

Lead Sponsor

PharmaKing
All Listed Sponsors
lead

PharmaKing

INDUSTRY